ClinicalTrials.gg
CompletedNCT06265012PHV01Updated Sep 5, 2025

Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects

A Phase 1 interventional study of PHV01 and Placebo in Marburg Virus Disease, sponsored by Public Health Vaccines LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Public Health Vaccines LLC · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1 randomized, single-blind, placebo-controlled, ascending dose study to evaluate the safety and immunogenicity of rVSV∆G-MARV-GP [Angola] (PHV01, Marburg Virus glycoprotein [MARV GP] Vaccine) in healthy adults. PHV01 is a live, attenuated rVSV vaccine expressing the MARV GP. The main questions it aims to answer are:

  • Which dose of PHV01 is safe to administer to, and well-tolerated by healthy adult subjects?
  • What is the immunologic response (Marburg-specific Immunoglobulin G (IgG) ELISA antibody and neutralizing antibodies) to each dose level?

Participants will receive 1 intramuscular injection of PHV01 or placebo on Day 1 and will be followed for 181 days.

Read the detailed description

Participants will be randomly assigned to vaccine or placebo in four dose cohorts, starting with evaluation of safety using a sentinel group at each dose level, followed by dosing of the rest of the group in the next cohort. That next cohort will also dose the sentinel group with the next higher dose.

02

Conditions studied

  • Marburg Virus Disease

Keywords

  • live, attenuated vaccine
  • Marburg virus
  • PHV01 (rVSV-MARV GP) vaccine
  • recombinant vesicular stomatitis virus
03

In context

Lead sponsor

Public Health Vaccines LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or non-pregnant, non-lactating females, age 18-60 years
  • Given written
  • No health problems
  • Negative test for SARS-CoV-2
  • Agree to avoid conception through Day 29
  • Agree to minimize blood and body fluid exposures to others after vaccination through Day 29
  • Agree to avoid exposure to persons after vaccination through Day 29

Exclusion criteria

Exclusion Criteria:

  • Prior infection with Marburg virus, related filovirus, or Ebola virus
  • Prior infection with vesicular stomatitis virus (VSV)
  • Received any VSV-vectored vaccine
  • of ≥ 35
  • Household contact who is immunodeficient, or on medication
  • , , -1, HIV-2, history of long COVID, diabetes, atopic dermatitis (eczema), chronic inflammatory disease, or autoinflammatory disorder, , chronic or active neurologic disorder
  • History of severe reactions to any vaccine or history of severe allergies
  • Receipt of product up to 30 days prior to randomization
  • Receipt of licensed or authorized non- within 14 days of planned study immunization (30 days for live vaccines).
  • Known allergy to components of PHV01
  • Injection sites obscured by tattoos or physical condition
  • Significant psychiatric or medical condition or laboratory abnormality on screening
  • History of Guillain Barre Syndrome or any chronic or acute neurological disorder
  • Alcohol or illicit drug abuse within past 5 years
  • Pregnant or lactating female
  • Administration of blood or IgG within 60 days preceding study
  • Administration of systemic chronic immunosuppressants (defined as more than 14 days) or other immune modifying drugs within 6 months of study entry
  • History of blood donation within 60 days of study
  • Unwilling to undergo diagnostic evaluation of rash (skin , if indicated) or joint symptoms (arthrocentesis if indicated by joint effusion), in both cases if acceptable to subject
  • Elective surgery planned during the study period
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group A, Low Dose PHV01

    Group A (10 subjects) PHV01 @ 10\^5 pfu/dose given once

    Biological: PHV01

  • Experimental
    Group B, Medium Dose PHV01

    Group B (10 subjects) PHV01 @ 10\^6 pfu/dose given once

    Biological: PHV01

  • Experimental
    Group C, Hjigh Dose PHV01

    Group C (10 subjects) PHV01 @ 10\^7 pfu/dose given once

    Biological: PHV01

  • Placebo comparator
    Group D, Placebo

    Group D (6 subjects) Placebo given once

    Biological: Placebo

Interventions

  • BiologicalPHV01

    Marburg virus vaccine

  • BiologicalPlacebo

    Lactated Ringer's Solution

06

What researchers measure

Primary outcomes

  1. Solicited Adverse Events (AEs)

    Incidence and severity of solicited injection site \[(arm pain, local tenderness, erythema (redness), and induration (swelling/firmness)\] and systemic AEs

    Time frame: Study Days 1-15

  2. Unsolicited AEs

    Incidence and severity of unsolicited AEs

    Time frame: Study Days 1-29

  3. Other AEs

    Incidence and severity of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)

    Time frame: Study Days 1-181

  4. Immunogenicity, Antibodies (Ab)

    Geometric mean titers (GMT) of Marburg GP protein-specific IgG antibody as measured by enzyme-linked immunosorbent assay (ELISA) on days 1 and 29

    Time frame: Injection through 28 days

  5. Immunogenicity, Neutralizing antibodies (NEUT)

    PsVNT50 and PsVNT80 MARV GP-specific neutralizing antibodies titers

    Time frame: Injection through 28 days

07

Study locations

1 site
  • CenExel RCA
    Hollywood, Florida 33024, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Sep 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 20, 2024
StartActual
Feb 5, 2024
Primary completionActual
Sep 23, 2024
CompletionActual
Sep 23, 2024
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06265012
Lead sponsor
Public Health Vaccines LLC
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Feb 5, 2024
Primary completion
Sep 23, 2024
Completion
Sep 23, 2024
Last update
Sep 5, 2025

Study contacts

Joan Fusco, PhD
study chair · Public Health Vaccines
Richard Kenney, MD
study director · Public Health Vaccines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion